Citryll gains Series B funds to develop NET-targeting antibody
Pharmaceutical Technology
DECEMBER 9, 2024
Citryll has secured an oversubscribed Series B funding round, raising 85m ($89.8m) to advance the clinical development of CIT-013.
Antibody Clinical Development Development 
Triventi secures $92m to advance clinical development of antibody therapy
Pharmaceutical Technology
OCTOBER 26, 2023
The Series A funds will go towards the clinical development of TRIV-509, with plans for a proof-of-concept atopic dermatitis study.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Astellas and Sutro partner to develop immunostimulatory ADCs
Pharmaceutical Technology
JUNE 28, 2022
Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.
Development 
264
264 
Adcentrx raises funds to advance ADCs into clinical development
Pharmaceutical Technology
APRIL 26, 2023
Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development. Adcentrx Therapeutics is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases.
Astellas to support development of Taysha’s gene therapy programmes
Pharmaceutical Technology
OCTOBER 25, 2022
Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.
Gene Therapy 264
264 
Gilead partners with MacroGenics for bispecific antibody development
Pharmaceutical Technology
OCTOBER 18, 2022
Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. Under the deal, the companies will leverage MacroGenics’ DART platform to develop MGD024 as well as two further bispecific research programmes.
Antibody 130
130 
Samsung Biologics to help Enzolytics advance clinical development of mAbs
BioPharma Reporter
OCTOBER 11, 2021
Samsung Biologics and Enzolytics have entered into a strategic CDMO partnership agreement targeting monoclonal antibody production.
Upstream Bio raises funds to advance clinical development of UPB-101
Pharmaceutical Technology
JUNE 9, 2023
It is also preparing for a swift transition to Phase III development. A new recombinant fully human immunoglobulin G1 monoclonal antibody, UPB-101, is now being evaluated in a Phase 1b trial to treat asthma. It targets the human thymic stromal lymphopoietin receptor to inhibit signalling.
Nona Biosciences and ModeX Therapeutics partner for antibodies discovery
Pharmaceutical Technology
MAY 24, 2023
HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.
Antibody 147
147 
New inhaled SARS-CoV-2 antibody treatment set to enter clinical trials
BioPharma Reporter
DECEMBER 13, 2021
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
Antibody 140
140 
How Can You Manage the Complexity of Early Phase Clinical Development?
XTalks
JUNE 4, 2024
In the ever-evolving landscape of pharmaceutical development, the complexity of early phase clinical trials is increasing. This surge in complexity is driven by escalating drug development costs, heightened competition and advanced scientific innovations. And that has a lot of downstream consequences.” This trend, which Dr.
Syncromune and Eucure enter antibody licence deal
Pharmaceutical Technology
OCTOBER 19, 2022
Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing.
Antibody 130
130 
China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma
Pharmaceutical Technology
MAY 22, 2023
SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).
Immune Response 273
273 
TORL scores $158m in Series B2 to advance ADC cancer therapies
Pharmaceutical Technology
APRIL 10, 2024
TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.
Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval
Pharmaceutical Technology
JUNE 19, 2024
Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.
Antibody 100
100 
AbbVie begins trials of COVID-19 antibody therapy
pharmaphorum
DECEMBER 16, 2020
AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.
Antibody 98
98 
Regeneron and CytomX partner to develop bispecific cancer therapies
Pharmaceutical Technology
NOVEMBER 18, 2022
Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. Under the deal, the companies will work together on the discovery activities for identifying and validating the conditionally active bispecific antibodies.
Development 130
130 
Gilead to acquire global rights of Trodelvy from Everest
Pharmaceutical Technology
AUGUST 16, 2022
Gilead Sciences has entered an agreement with Everest Medicines to acquire complete rights to develop and market Trodelvy (sacituzumab govitecan) in Greater China, Singapore, South Korea, Philippines, Vietnam, Thailand, Indonesia, Mongolia and Malaysia. Gilead will also have a chance to hire Everest staff working on the Trodelvy programme.
Medicine 255
255 
Evaxion and ExpreS²ion partner to develop new CMV vaccine
Pharmaceutical Technology
DECEMBER 6, 2022
Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. Evaluations will follow this method in preclinical models of Evaxion.
Vaccination 130
130 
Boehringer takes alteplase to phase 3 for COVID, but drops antibody
pharmaphorum
JULY 27, 2021
Boehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme later this year. The hope was that an inhaled antibody would reach higher levels in the lung, where it is most needed, than systemic antibodies.
Antibody 98
98 
Fusion Pharmaceuticals receives FDA IND approval for FPI-2068
Pharmaceutical Technology
APRIL 13, 2023
FPI-2068 is a bispecific targeted alpha therapy (TAT) being jointly developed by Fusion and AstraZeneca under a multi-asset collaboration agreement. Fusion stated that FPI-2068 will become the first programme to enter clinical development under its collaboration agreement with AstraZeneca.
Manufacturing challenges set back development progress of cell therapies in oncology
Pharmaceutical Technology
NOVEMBER 21, 2022
The clinical hold placed by Instil Bio on DELTA-1 means that Instil Bio will have to re-evaluate its manufacturing process and will lose precious clinical development time on its way to a biologics license application (BLA). Only 29% of patients successfully received the CAR-T product within 12 months, and 31.9%
Manufacturing 147
147 
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
Pharma Times
JUNE 2, 2023
BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development - News - PharmaTimes
Antibody 110
110 
ExeVir ready for clinic with variant-targeting llama antibody
pharmaphorum
MARCH 9, 2021
Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. Ablynx, which is now a subsidiary of Sanofi following a $4.8
Antibody 98
98 
US companies drive 2023 drug launches positioned for blockbuster success by 2028
Pharmaceutical Technology
MAY 30, 2023
Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. which is the licensee of lebrikizumab, recently reported favourable outcomes for lebrikizumab through a novel secondary analysis of the Phase III clinical development programme.
Drugs 264
264 
Ono Pharmaceutical enters research deal with Monash University
Pharmaceutical Technology
JANUARY 16, 2023
Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”.
Research 130
130 
EC grants approval for BioMarin’s gene therapy to treat Hemophilia A
Pharmaceutical Technology
AUGUST 25, 2022
The treatment is indicated for patients with no history of Factor VIII inhibitors and any detectable antibodies to adeno-associated virus serotype 5 (AAV5). The approval is based on comprehensive data from the clinical development programme of Roctavian, including two-year findings from the international Phase III GENEr8-1 clinical trial.
Gene Therapy 264
264 
Immuno-oncology market set to grow in billions, but access concerns remain
Pharmaceutical Technology
MAY 26, 2023
GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies. There are currently over 700 immuno-oncology products in Phase I-III of development in the eight major markets, said Chalk. PD1, BCMA and PDL1 follow as the most common targets.
Marketing 264
264 
Mayo Clinic researchers develop new antibody test to diagnose MS
Scienmag
MARCH 24, 2022
Mayo Clinic researchers have validated a new antibody test to diagnose multiple sclerosis (MS), a potentially disabling disease of the brain and spinal cord. An antibody typically consists of two immunoglobulin heavy chains and […]. ROCHESTER, Minn. Nearly 1 million people in the U.S.
FibroGen and Fortis sign exclusive licence deal for mCRPC drug candidate
Pharmaceutical Technology
MAY 9, 2023
FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is a natural fit with our research and development capabilities and expertise.
Drugs 130
130 
Pyxis Oncology signs agreement to buy Apexigen
Pharmaceutical Technology
MAY 25, 2023
Apexigen discovers and develops a new generation of antibody therapeutics to treat cancer, along with new immuno-oncology products to harness the immune system to combat and eradicate cancer. Pyxis Oncology will issue 0.1725 shares of its common stock, with par value of $0.001 per share, for each Apexigen share.
Antibody 130
130 
Pheon launches to progress ADCs for solid tumour treatment
Pharmaceutical Technology
SEPTEMBER 30, 2022
Pheon Therapeutics has announced its launch to progress new antibody-drug conjugates (ADCs) for treating solid tumours. The latest financing will aid the company in progressing its lead ADC programme to clinical proof-of-concept (PoC) and validate the new ADC pipeline. .
Antibody 130
130 
Numab raises $110m to develop cancer bispecific antibodies
pharmaphorum
MAY 20, 2021
Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.
Antibody 52
52 
Pfizer/BioNTech Begin Studies for Third Booster Dose and Development of COVID-19 Vaccine Variants
XTalks
MARCH 1, 2021
The study is part of a broad development plan to assess the durability of the immunogenic responses elicited by its vaccine and the emergence of new SARS-CoV-2 variants. The third dose will be administered to the participants regardless of antibody titer levels. The study will be a part of current Phase I, II and III trials.
Vaccination 111
111 
AION Labs launches combinAble.AI to revolutionize antibody design with AI
Outsourcing Pharma
MARCH 11, 2024
In a bid to reshape the landscape of targeted antibody design, AION a creative venture studio based in Israel has introduced CombinAble.AI.
Antibody 80
80 
Japan grants approvals for Merck’s Keytruda to treat different cancers
Pharmaceutical Technology
SEPTEMBER 28, 2022
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted four new approvals for Merck ’s (MSD outside North America) humanised monoclonal antibody, Keytruda (pembrolizumab), to treat various types of cancers. With the latest development, the antibody is indicated for 23 usages in 13 different cancer types of cancer in the country.
Antibody 147
147 
AbbVie and HotSpot sign partnership for autoimmune disease therapy
Pharmaceutical Technology
DECEMBER 7, 2022
The partnership will utilise the Smart Allostery drug discovery platform of HotSpot to develop the first and only small molecule inhibitor of IRF5 for these diseases. HotSpot is also entitled to get option fees and research and development milestone payments totalling up to $295m.
Development 147
147 
Merck wins regulatory approval for combination therapy to treat la/mUC
Pharmaceutical Technology
APRIL 4, 2023
KEYTRUDA is an anti-PD-1 therapy developed by Merck, while Padcev has been developed by Astellas and Seagen. Merck stated that the regulatory approval represents the first of its kind received by an anti-PD-1 therapy in combination with an antibody-drug conjugate for use in targeted patients in the US.
Antibody 130
130 
STRO-002 by Sutro Biopharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 19, 2023
STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Antibody 100
100 
EC approves AstraZeneca-Sanofi’s Beyfortus for preventing RSV in infants
Pharmaceutical Technology
NOVEMBER 7, 2022
The latest approval in the EU is based on findings from Beyfortus's clinical development programme, including the Phase III MELODY, Phase II/III MEDLEY and Phase IIb clinical trials. Beyfortus is a long-acting antibody. compared with placebo through day 151. compared with placebo through day 151.
Clinical Trials 162
162 
FibroGen to receive funding for commercialisation of pamrevlumab
Pharmaceutical Technology
MAY 2, 2023
The loan also provides capital to sustain the development of the company’s pre-clinical pipeline and will be made accessible to the company in three tranches. FibroGen CEO Enrique Conterno stated: “With the current momentum across our development programmes, this financing strengthens our balance sheet.
Clinical Trials 130
130 
ASP-2138 by Xencor for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-2138 is under clinical development by Xencor and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Antibody 100
100 
ASP-2138 by Xencor for Gastric Cancer: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-2138 is under clinical development by Xencor and currently in Phase I for Gastric Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is administered through intravenous drip route.
Antibody 100
100 
ASP-2138 by Xencor for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-2138 is under clinical development by Xencor and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Antibody 100
100 
Let's personalize your content